|
Consolidation in the biopharmaceutical industry looks set to continue into 2007 and beyond as the licensing and M&A trend continues. Generics companies must consolidate to remain competitive. Pharmaceutical companies are relying on biotechs and academics to fill their drug pipelines, which are uncharacteristically low following the generics boom, shelved drugs and extreme development costs.
The affordability vs. innovation debate is still raging with generics manufacturers driving down the cost of drugs, while pharmaceutical companies aggressively defend their intellectual property. There is also an emerging threat from enterprising ‘ethical pharmaceuticals’; by changing the molecular structure of existing drugs, patent protection no longer applies.
Biosimilars regulation is a key focus area for 2007, with companies debating if the process really is the product. To what extent will clinical trials be needed for biosimilars and will their success mirror that of traditional generics?
Business models are also changing; Indian generics companies are seeking to be innovative and pharmaceutical companies are expanding into the generics sector and launching their own generic versions. Generics manufacturers are also looking to break into the European market due to competition and pricing pressure in North America.
Areas to be covered:
Pre-congress briefing day 25th September 2007
Ethical Medicine: the future of Pharma?
Innovations vs. affordability; one argument, two perspectives
Conference day one 26th September 2007
Generic medicines in Europe; regional considerations in a global market
Biosimilars: regulatory, manufacturing and marketing aspects
Conference day two 27th September 2007
Adapting business models in response to the generics and biosimilars boom
Generic manufacturers in India and emerging markets
|
